InforSense and National Cancer Institute Enter Five-year Agreement
News Sep 07, 2005
InforSense Ltd. has announced that the National Cancer Institute (NCI), the US Federal Government's principal agency for cancer research, has chosen InforSense technology for high-throughput genetic data analysis in cancer research.
Investigators at the Core Genotyping Facility (CGF) of the NCI, Gaithersburg, MD, USA, will use InforSense’s workflow-based integrative analytics platform, InforSense KDE, for rapid application development for their own research and also plan to publish analysis methods via a web portal to the wider research community.
"Investigators require access to the latest analysis techniques to advance their research. Therefore, creating the informatics infrastructure to compose and deliver these methods is a high priority at the CGF,” said Dr. Meredith Yeager, Scientific Director, Core Genotyping Facility, NCI.
“After an extensive review of the available commercial and open source options, we recognized that InforSense KDE is able to provide the functionality, flexibility, and scalability we need to support our research, and to develop caBIG™ (Cancer Biomedical Informatics Grid ) compatible applications.”
“We are delighted that NCI has selected InforSense KDE for their genetics analysis platform,” commented Prof. Yike Guo, CEO and Founder, InforSense. He adds, “InforSense KDE is designed to enable scientists to easily build and publish their analytical applications by accessing and integrating diverse data, methods and services available within a large organization.”
Further he said, “The agreement with NCI underlines our commitment to establish InforSense KDE as the standard platform for application development within an informatics grid.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.